Alastair Greystoke Medical Oncologist Newcastle

Alastair Greystoke Medical Oncologist Newcastle – Leading Innovation in Cancer Care

Alastair Greystoke Medical Oncologist Newcastle leads clinical excellence and research innovation in thoracic oncology. As an Honorary Medical Oncologist at Newcastle’s Northern Centre for Cancer Care and a Lecturer at Newcastle University, Dr Greystoke combines cutting-edge research with compassionate patient care.

Since 2014, Dr Greystoke has dedicated his expertise to improving outcomes for patients with lung cancer. After spending eight years at Manchester’s Christie NHS Trust, he brought his deep knowledge and passion for drug development to the Freeman Hospital in Newcastle.

Specialised Focus in Lung Cancer and Drug Development

Dr Greystoke specialises in lung cancer, frailty in cancer, personalised medicine, and early-phase drug trials. His work helps patients receive treatments tailored to their unique needs. In fact, he plays a pivotal role in developing new anti-cancer drugs targeting thoracic malignancies.

Alastair Greystoke Medical Oncologist Newcastle at the Forefront of Clinical Trials

At the Sir Bobby Robson Early Clinical Trials Centre, Dr Greystoke helps design and deliver first-in-human studies. These trials bring hope to patients with limited options. His work bridges the gap between lab discoveries and real-world therapies.

Driving Genomic Innovation Across the North East

In his role as Clinical Lead for Cancer for the Yorkshire, Hull and North East England Genomic Laboratory Hub, Dr Greystoke drives the integration of genomics into cancer care. This work allows oncologists to make more informed treatment decisions, improving patient outcomes across the region.

Academic Leadership and Biomarker Discovery

Dr Greystoke leads the Pharmacodynamic Biomarker Team at the Centre for Cancer Research, Newcastle University. His team focuses on identifying biomarkers that measure treatment responses. These tools accelerate the development of safer, more effective cancer therapies.

Pioneering Collaborative Research Platforms

As Joint Chief Investigator of the CONCORDE platform, Dr Greystoke leads research exploring the addition of novel drugs to radical radiotherapy in non-small cell lung cancer (NSCLC). His collaborative approach ensures that clinical advancements benefit as many patients as possible.